LGMDR9 Clinical Trial - Global FKRP Registry

Status Recruiting

Clinical Trial Summary

Mutations in the Fukutin Related Protein (FKRP) gene cause the condition Limb Girdle Muscular Dystrophy type R9 (LGMDR9) also known as LGMD2I, and the rarer conditions Congenital Muscular Dystrophy (MDC1C), Muscle Eye Brain Disease (MEB) and Walker-Warburg Syndrome (WWS). LGMDR9 is the most common FKRP-related condition, and is especially prevalent in Northern Europe. The aim is to facilitate a questionnaire based research study in order to better characterise and understand the disease globally. By maintaining a global registry this will help identify potential participants eligible for clinical trials in the future.

Clinical Trial Description

The Global FKRP Registry (https://www.fkrp-registry.org/) is an international registry for patients with an FKRP-related condition; no experimental intervention is involved. Patients will receive information on the most up to date standards of care relating to their disease and may be invited to participate in relevant clinical trials. Their data will be updated annually and stored indefinitely, or until they request their data to be removed. The data will be collected via an online form and will be stored on a secure server based in the United Kingdom and looked after by the registry staff at Newcastle University. Data collected from patients will include demographic information, diagnosis, current condition, age of onset, medication, contractures, family history and results of genetic testing, if available. Other optional questionnaires will focus on patients' pain and quality of life. Further information collected from patients' doctors will include, heart and lung function, muscle strength, muscle and brain MRI findings and genetics. The FKRP registry is funded by LGMD2i Research Fund and CureLGMD2i. The primary objectives of the Global FKRP Registry are to: - Accelerate and facilitate clinical trials by locating potential research subjects quickly and efficiently - Facilitate in the planning of clinical trials - Assist the neuromuscular community with the development of recommendations and standards of care - Characterise and describe the FKRP population as a whole, enhancing the understanding of the prevalence throughout the world. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04001595
Study type	Observational [Patient Registry]
Source	Newcastle University
Contact	Patient Registry Manager and Curator
Phone	0191 2418640
Email	fkrpregistry@newcastle.ac.uk
Status	Recruiting
Phase
Start date	November 2013
Completion date	December 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05409079` - Schulze Muscular Dystrophy Ability Clinical Study	N/A
Active, not recruiting	`NCT05906251` - A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related)	Phase 1
Recruiting	`NCT05230459` - A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)	Phase 1/Phase 2
Recruiting	`NCT03981289` - Defining Clinical Endpoints in Limb Girdle Muscular Dystrophy (LGMD)
Completed	`NCT02836418` - Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD)	Phase 1/Phase 2
Active, not recruiting	`NCT03930628` - Limb-Girdle Muscular Dystrophy Type 2I in Norway
Recruiting	`NCT05618080` - Trial Readiness and Endpoint Assessment in LGMD R1
Completed	`NCT01066455` - Cardiac Outcome Measures in Children With Muscular Dystrophy	N/A
Active, not recruiting	`NCT05206617` - 3 Year Follow up on ANO5 Patients
Completed	`NCT01126697` - Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies	Phase 2/Phase 3
Withdrawn	`NCT02245711` - Cell Therapy in Limb Girdle Muscular Dystrophy	Phase 1
Withdrawn	`NCT02050776` - Stem Cell Therapy in Limb Girdle Muscular Dystrophy	Phase 1
Active, not recruiting	`NCT05876780` - A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)	Phase 1
Recruiting	`NCT06378203` - Rehabilitation in Muscular Dystrophies From the Hospital Facility to the Home: Pilot Project [RIMUDI]	N/A
Completed	`NCT04202627` - Biomarker Development in LGMD2i
Not yet recruiting	`NCT06390566` - Evolution of the Functional and Muscular State of Patients With Muscular Dystrophy 2A Belts
Completed	`NCT01081080` - Cardiac Magnetic Resonance in Children With Muscular Dystrophy	N/A
Recruiting	`NCT05102799` - MRI-phenotyping of Patients With Pathogenic Anoctamin 5 Variants

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.